MedTrace Logo

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

NCT05798819 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 424

Last updated 2023-04-05

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.

Conditions

  • Persistent, Recurrent, or Metastatic Cervical Cancer

Interventions

DRUG

GLS-010

IV infusion

DRUG

Placebo

IV infusion

DRUG

paclitaxel

IV infusion

DRUG

cisplatin

IV infusion

DRUG

carboplatin

IV infusion

DRUG

bevacizumab

IV infusion

Sponsors & Collaborators

  • Guangzhou Gloria Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-05-01
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05798819 on ClinicalTrials.gov